SCHEMBL5160926

SCHEMBL5160926

CCN1C(=O)SC(=Cc2ccc(-c3ccc([N+](=O)[O-])cc3OC)o2)C1=O

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
MAPT P10636 3/20 0.67
POLB P06746 2/20 0.67
ALDH1A1 P00352 2/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
MCL1 Q07820 1/20 0.67
TDP1 Q9NUW8 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.52
SLC1A3 P43003 2/20 0.51
F5 P12259 1/20 0.49
XPA P23025 1/20 0.49
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
ITGB2 P05107 2/20 0.47
ITGAM P11215 2/20 0.47
PIK3CG P48736 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160915 1.00 MEN1 (0.67) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5145434 0.89 MEN1 (0.60) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5145430 0.89 MEN1 (0.60) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5168454 0.88 SLC1A3 (0.68) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5168445 0.88 SLC1A3 (0.68) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5169574 0.82 MAP3K5 (0.62) MEN1KMT2AMAPTPOLBL3MBTL1
SCHEMBL5169570 0.82 MAP3K5 (0.62) MEN1KMT2AMAPTPOLBL3MBTL1
SCHEMBL5164940 0.82 MAPT (0.57) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5164943 0.82 MAPT (0.57) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5147353 0.78 PIK3CG (0.74) MEN1KMT2AMAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MEN1 4004/4885KMT2A 4410/4885MAPT 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.